Expert Ratings for Regulus Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their bullish opinion on Regulus Therapeutics (NASDAQ:RGLS) stock, with an average price target of $9.0, representing a 55.0% decrease from the previous average price target of $20.00. Analysts derive their information from company conference calls, financial statements, and conversations with insiders.
June 28, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have a bullish stance on Regulus Therapeutics (NASDAQ:RGLS), but the average price target has decreased by 55.0% to $9.0.
The bullish stance of analysts indicates a positive outlook for the company. However, the significant decrease in the average price target could indicate a potential downside, leading to a neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100